Using patient-derived tumor organoids, researchers have identified which therapies may be most effective for individual sarcoma patients.

Regarding distributions, we view Novartis’ dividends and share repurchases as about right. Novartis has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, ...

Figure 1. Initial angiograms (A, B). A 2.5- X 80-mm Serranator PTA Serration Balloon for vessel preparation of the occluded PT artery prior to use of a bioresorbable scaffold (BRS) (C). Completion ...

Tablets under 20000 have robust constructions. If you require a study buddy, a portable office or even an entertainment device, tablets under Rs. 20,000 are the best options for cost-effective and ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

until now. Mountain View recently confirmed that a consumer desktop mode is still happening, and devs can test out the new functionality on the Pixel Tablet using the latest developer preview.

One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney cancer drug as it ... chemotherapy Afinitor. The results from the ...

In the Afinitor group, reasons for discontinuation were progressive ... “The most common any-grade adverse drug reactions had a median time to onset of less than two months.” The median duration of ...

to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end ...

In the everolimus arm, reasons for discontinuation were progressive ... “The most common any-grade adverse drug reactions had a median time to onset of less than 2 months.” The median durations of ...

Google is testing a new feature for Android tablets that will let you resize apps freely and arrange them on your screen at will, making it easier to juggle multiple tasks. The “desktop ...